TY - JOUR
T1 - Toward the establishment of standardized in vitro tests for lipid-based formulations. 5. Lipolysis of representative formulations by gastric lipase
AU - Bakala-N'Goma, Jean-Claude
AU - Williams, Hywel David
AU - Sassene, Philip Jonas
AU - Kleberg, Karen
AU - Calderone, Marilyn
AU - Jannin, Vincent
AU - Igonin, Annabel
AU - Partheil, Anette
AU - Marchaud, Delphine
AU - Jule, Eduardo
AU - Vertommen, Jan
AU - Maio, Mario
AU - Blundell, Ross
AU - Benameur, Hassan
AU - Mullertz, Anette
AU - Pouton, Colin William
AU - Porter, Christopher John
AU - Carriere, Frederic
PY - 2015
Y1 - 2015
N2 - Purpose: Lipid-based formulations (LBF) are substrates for digestive lipases and digestion can significantly alter their properties and potential to support drug absorption. LBFs have been widely examined for their behaviour in the presence of pancreatic enzymes. Here, the impact of gastric lipase on the digestion of representative formulations from the Lipid Formulation Classification System has been investigated. Methods: The pHstat technique was used to measure the lipolysis by recombinant dog gastric lipase (rDGL) of eight LBFs containing either medium (MC) or long (LC) chain triglycerides and a range of surfactants, at various pH values [1.5 to 7] representative of gastric and small intestine contents under both fasting and fed conditions. Results: All LBFs were hydrolyzed by rDGL. The highest specific activities were measured at pH 4 with the type II and IIIA MC formulations that contained Tween®85 or Cremophor EL respectively. The maximum activity on LC formulations was recorded at pH 5 for the type IIIA-LC formulation. Direct measurement of LBF lipolysis using the pHstat, however, was limited by poor LC fatty acid ionization at low pH. Conclusions: Since gastric lipase initiates lipid digestion in the stomach, remains active in the intestine and acts on all representative LBFs, its implementation in future standardized in vitro assays may be beneficial. At this stage, however, routine use remains technically challenging.
AB - Purpose: Lipid-based formulations (LBF) are substrates for digestive lipases and digestion can significantly alter their properties and potential to support drug absorption. LBFs have been widely examined for their behaviour in the presence of pancreatic enzymes. Here, the impact of gastric lipase on the digestion of representative formulations from the Lipid Formulation Classification System has been investigated. Methods: The pHstat technique was used to measure the lipolysis by recombinant dog gastric lipase (rDGL) of eight LBFs containing either medium (MC) or long (LC) chain triglycerides and a range of surfactants, at various pH values [1.5 to 7] representative of gastric and small intestine contents under both fasting and fed conditions. Results: All LBFs were hydrolyzed by rDGL. The highest specific activities were measured at pH 4 with the type II and IIIA MC formulations that contained Tween®85 or Cremophor EL respectively. The maximum activity on LC formulations was recorded at pH 5 for the type IIIA-LC formulation. Direct measurement of LBF lipolysis using the pHstat, however, was limited by poor LC fatty acid ionization at low pH. Conclusions: Since gastric lipase initiates lipid digestion in the stomach, remains active in the intestine and acts on all representative LBFs, its implementation in future standardized in vitro assays may be beneficial. At this stage, however, routine use remains technically challenging.
KW - digestion
KW - drug delivery
KW - lipid formulation
KW - lipolysis
KW - stomach
UR - http://link.springer.com.ezproxy.lib.monash.edu.au/content/pdf/10.1007%2Fs11095-014-1532-y.pdf
U2 - 10.1007/s11095-014-1532-y
DO - 10.1007/s11095-014-1532-y
M3 - Article
SN - 0724-8741
VL - 32
SP - 1279
EP - 1287
JO - Pharmaceutical Research
JF - Pharmaceutical Research
IS - 4
ER -